[Federal Register Volume 63, Number 138 (Monday, July 20, 1998)]
[Notices]
[Pages 38840-38842]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-19146]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Murine Intracisternal a Particle Constitutive Transport Elements
and Uses Thereof
BK Felber, C Tabernero, AS Zolotukhin (NCI)
Serial No. 60/070,204 filed 31 Dec 97
Licensing Contact: Robert Benson, 301/496-7056 ext. 267
This invention concerns recombinant attenuated HIV strains useful
as vaccines. HIV regulates its expression by controlling the nuclear
transport of unspliced mRNA encoding structural proteins. HIV utilizes
the Rev/RRE system. RRE (Rev. Responsive Element) is an HIV encoded
nucleo-cytoplasmic transport element (NCTE), which is part of every HIV
RNA encoding the structural genes (gas/pol and env). Rev is an HIV
encoded protein which binds to the RRE. This interaction is essential
for the nucleo-cytoplasmic transport of the RRE-containing viral mRNAs
and the expression of Gap/Pol and Env proteins. The inventors have
produced an attenuated HIV by disabling rev/RRE, by point mutations,
and inserting in its place a novel murine NCTE, isolated form an
intracisternal A-type particle (IAP). The resultant HIV is attenuated
between 50 and 200 fold compared to wild-type HIV. Claimed are the
novel murine NCTE, recombinant retroviruses comprising the NCTE, and
vaccines. The use of another NCTE is described in Zolotukhin et al.,
(1994) J. Virology 68:7944-7952.
Design and Construction of Non-Infectious Human Retroviral Mutants
Deficient in Genomic RNA
RJ Gorelick, LO Arthur, A Rein, LE Henderson, S Oroszlan (NCI)
U.S. Patent No. 5,674,720 issued 07 Oct 97
Licensing Contract: Robert Benson, 301/496-7056 ext. 267
This invention describes methods for generating non-replicating
(i.e. non-infectious) virus-like particles that mimic HIV-1, SIV and
other retroviruses, which are capable of generating a protective immune
response. In addition to being replication defective, these virus like
particles are deficient in packaged genomic RNA but have the added
benefit of a normal compliment of viral and cellular proteins that
remain in their native conformations. Also claimed are methods of
making the mutant retroviruses which may potentially be used as
immunogens for vaccines, particularly against HIV-1. The basis of the
method and the mutant viruses of the claims is the finding that a
conserved amino acid sequence motif, found in the nucleocapsid domain
of
[[Page 38841]]
the Gag precursor polyprotein of all retroviruses, when mutated
resulted in virions with much lower or zero infectivity. This concept
has been tested in the primate lentivirus, SIV, which is related to
HIV-1. Mutations were introduced into the gene coding for the conserved
sequence motif found in the nucleocapsid domain of the Gag precursor
polyprotein of SIV. The viruses obtained upon transfection were
defective in replication. Plasmid DNA containing the mutated provirus
was injected into five pig tailed macques and the vector without the
provirus was injected into four control animals. The vaccinated animals
were either partially or fully protected when challenged with
infectious SIV(Mne) whereas three of the four control animals became
persistently infected and developed AIDS as indicated by a marked
decline in CD4 cell numbers. The invention has been filed in foreign
countries and has been granted in Europe (No. 91900636.1) and Japan
(No. Hei 7-16420).
The Application of Induction Tolerance by Oral Feeding of Myelin
Basic Protein to the Generation of Increased Resistance to Stroke
KJ Becker, JM Hallenbeck, RM McCarron (NINDS)
Serial No. 08/994,293 filed 19 Dec 97
Licensing Contact: Stephen Finley, 301/496-7735 ext. 215
In vivo experiments have shown that immunosuppression in the brain
can be achieved through oral tolerance to myelin basic protein (MBP).
Following exposure to MBP again which has the effect of suppressing the
inflammatory reaction associated with stroke. This possible new means
of minimizing the severity of damage from stroke, the number three
killer of Americans and leading cause of disability, does not result in
detrimental systemic side effects as other immunosuppressive agents do.
This treatment could be administered to those considered at
significantly increased risk for a stroke including those with a
previous stroke, diabetes mellitus, hypertension, hypercholesteremia,
or a history of smoking as well as those undergoing a medical or
surgical treatment which increases the possibility of an ischemic
event.
Salivary Prolactin Test for Serotonergic Activity
JD Higley (NIAAA), S Lindell (NICHD)
Serial No. 60.082,126 filed 16 April 98
Licensing Contact: Stephen Finley, 301/496-7735 ext. 215
A noninvasive diagnostic assay improves on previous methods for
determining central serotonin functioning, an indicator of
susceptibility to aggression, alcohol abuse, obsessive-compulsive
disorder and eating disorders. Levels of salivary prolactin can be
assayed to determine susceptibility to the set of pysychiatric
disorders related to central serotonin functioning. Levels of salivary
prolactin were found to be positively correlated with levels of
cerebrospinal fluid (CSF) 5-hydroxyindol acetic acid (5-HIAA), the
current measurement of central serotonin functioning. Elevated CSF
levels of 5-HIAA are associated with obsessive-compulsive disorders,
and reduced levels are associated with violent behavior, alcohol abuse
and bulimia. There are an estimated 9 million alcoholics in the United
States and currently 0.5% of women 10 to 30 years old have anorexia
nervosa while 5% of college-age women have bulimia. The user-
friendliness and reduced costs of the saliva assay suggest possible
candidacy for mass screenings to determine susceptibility to various
psychiatric disorders.
Conjugate Vaccine for Salmonella Paratyphi A
E Konadu and S Szu (NICHD)
Serial No. PCT/US96/19978 filed 18 Dec 96
Licensing Contact: Robert Benson, 301/496-7056 ext. 267
This invention concerns a conjugate vaccine against Salmonella
paratyphi A comprising the o-specific polysaccharide bound to a carrier
protein. Salmonella paratyphi A infection causes enteritis and enteric
fever. The emergence of multidrug resistant strains has raised alarms.
The present invention offers a method of preventing the disease. The
conjugate is made by isolating lipopolysaccharide, detoxifying by
removing the lipid A, while retaining substantially all the O-acetyl
groups, and conjugating by known means to a carrier protein such as
tetanus toxoid or detoxified exoprotein A. In a Phase I clinical trial
the vaccine has been given to healthy adults and elicited anti-LPS IgG
levels at least 4-fold higher compared to preimmune serum in 85% of
volunteers. The invention is also described in Konadu et al., Infection
and Immunity 64(7), 2709-2715, 1996.
Cloning of GMEB 1 and 2: Two Proteins Involved in the Modulation of
Glucocorticoid Regulated Gene Transcription
S. Stoney Simons, Jr., et al. (NIDDK)
DDH Reference No. E-070-97/0 filed 25 Jul 97
Licensing Contact: Charles Maynard, 301/496-7735 ext. 243
This technology relates to a previously identified DNA element from
a naturally occurring gene that has the properties of causing
glucocorticoid induction at lower steroid concentrations than for other
glucocorticoid inducible genes in the same cell. This DNA element, also
called a glucocorticoid modulatory element, or GME, has been found to
involve two proteins of 88 and 67 kDa.
This technology has succeeded in cloning and characterizing both
the 67 kDa protein and the 88 kDa protein which together offer a unique
and not previously described method of using genetic engineering to
achieve selective regulation of glucocorticoid responsive genes. This
group of proteins appears to be members of a larger class of related
proteins which may have similar roles in modifying the activity of RNA
polymerase II transcriptional complex.
Gated RF Preamplifier for Use in Pulsed Radiofrequency Electron
Paramagnetic Resonance and MRI
RG Tschudin (NIDDK), R Murugesan (NCI), MK Cherukuri (NCI), JB Mitchell
(NCI), S Subramanian (NCI)
Serial No. 08/699,383 filed 19 Aug 96
Licensing Contact: John Fahner-Vihtelic, 201/496-7735 ext. 270
The present application describes a radiofrequency preamplifier
featuring very fast recovery after the transmit cycle to allow for
ultrafast data acquisition, intended for use in pulsed EPR, MRI and
related computed imaging applications. One advantage of this device is
that it allows the use of low frequency EPR, which offers better tissue
penetration during in vivo diagnostic studies. The invention permits
the use of a pulsed EPR method, which offers improved speed and
sensitivity over existing methods. A prototype device has been made and
the design has proven to work in an EPR system.
Lipopolysaccharide Carriers for Use in Vaccines
B Golding (FDA)
Serial No. 08/369,565 filed 06 Jan 95 (allowed)
Licensing Contact: Robert Benson, 301/496-7056 ext. 267
This invention is a new carrier for conjugate vaccines. The carrier
is lipopolysaccharide (LPS) isolated from Brucella abortus (BA). The
claims of the patent cover all conjugates comprising BA-LPS and an
antigen from an infectious agent or tumor. BA-LPS, like other LPSs from
gram-negative bacteria,
[[Page 38842]]
raises antibody responses in a T-independent fashion, which allows
antibodies to be raised in the absence of T cell help. BA-LPS is much
less toxic than LPS from other bacteria, and is much less potent than
other bacterial LPS in including inflammatory cytokines. Thus, BA-LPS
is much less likely to cause endotoxic shock. There are no foreign
patent rights. The invention is further described in Infection &
Immunity 61(5), pp. 1722-1729, 1993.
Dated: July 6, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 98-19146 Filed 7-17-98; 8:45 am]
BILLING CODE 4140-01-M
